258 related articles for article (PubMed ID: 38660314)
1. Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis.
Wang J; Guo Z; Shen M; Xie Q; Xiang H
Front Immunol; 2024; 15():1366489. PubMed ID: 38660314
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Tang L; Wang J; Lin N; Zhou Y; He W; Liu J; Ma X
Front Immunol; 2021; 12():800879. PubMed ID: 34992611
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota shed new light on the management of immune-related adverse events.
Tan B; Liu YX; Tang H; Chen D; Xu Y; Chen MJ; Li Y; Wang MZ; Qian JM
Thorac Cancer; 2022 Oct; 13(19):2681-2691. PubMed ID: 36043345
[TBL] [Abstract][Full Text] [Related]
5. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
6. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
8. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
9. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.
Zhou G; Zhang N; Meng K; Pan F
Front Immunol; 2022; 13():1001623. PubMed ID: 36389768
[TBL] [Abstract][Full Text] [Related]
10. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
11. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
12. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
13. The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.
Han X; Zang D; Liu D; Chen J
Front Immunol; 2022; 13():988849. PubMed ID: 36189293
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
15. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
Front Immunol; 2021; 12():788499. PubMed ID: 34956219
[TBL] [Abstract][Full Text] [Related]
16. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer.
Shroff GS; Strange CD; Ahuja J; Altan M; Sheshadri A; Unlu E; Truong MT; Vlahos I
Radiographics; 2022; 42(7):1956-1974. PubMed ID: 36240075
[TBL] [Abstract][Full Text] [Related]
17. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM
Front Immunol; 2021; 12():768957. PubMed ID: 34777387
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
20. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]